Literature DB >> 33006093

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Mohammed Eslam1, Shiv K Sarin2, Vincent Wai-Sun Wong3, Jian-Gao Fan4, Takumi Kawaguchi5, Sang Hoon Ahn6, Ming-Hua Zheng7,8, Gamal Shiha9,10, Yusuf Yilmaz11,12, Rino Gani13, Shahinul Alam14, Yock Young Dan15, Jia-Horng Kao16,17,18,19, Saeed Hamid20, Ian Homer Cua21, Wah-Kheong Chan22, Diana Payawal23, Soek-Siam Tan24, Tawesak Tanwandee25, Leon A Adams26, Manoj Kumar27, Masao Omata28,29, Jacob George30.   

Abstract

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its epidemiology, diagnosis, screening, assessment, and treatment. The document is intended for practical use and for setting the stage for advancing clinical practice, knowledge, and research of MAFLD in adults, with specific reference to special groups as necessary. The guidelines also seek to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector.

Entities:  

Year:  2020        PMID: 33006093     DOI: 10.1007/s12072-020-10094-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  273 in total

1.  An automatic device for the isolated rabbit heart preparation for testing cardioactive drugs.

Authors:  M Schmid; J Atkinson
Journal:  J Lab Clin Med       Date:  1975-04

2.  Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

Authors:  Chien-Hua Chen; Min-Ho Huang; Jee-Chun Yang; Chiu-Kue Nien; Chi-Chieh Yang; Yung-Hsiang Yeh; Sen-Kou Yueh
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

3.  Prevalence of and risk factors for fatty liver in a general population of Shanghai, China.

Authors:  Jian-Gao Fan; Jun Zhu; Xing-Jian Li; Lan Chen; Lui Li; Fei Dai; Feng Li; Shi-Yao Chen
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

Review 4.  The changing epidemiology of liver diseases in the Asia-Pacific region.

Authors:  Martin C S Wong; Jason L W Huang; Jacob George; Junjie Huang; Colette Leung; Mohammed Eslam; Henry L Y Chan; Siew C Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-01       Impact factor: 46.802

5.  Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China.

Authors:  Hong Li; You-Juan Wang; Ke Tan; Li Zeng; Li Liu; Feng-Jun Liu; Tao-You Zhou; En-Qiang Chen; Hong Tang
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2009-08

6.  Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.

Authors:  Jie Li; Biyao Zou; Yee Hui Yeo; Yuemin Feng; Xiaoyu Xie; Dong Hyun Lee; Hideki Fujii; Yuankai Wu; Leslie Y Kam; Fanpu Ji; Xiaohe Li; Nicholas Chien; Mike Wei; Eiichi Ogawa; Changqing Zhao; Xia Wu; Christopher D Stave; Linda Henry; Scott Barnett; Hirokazu Takahashi; Norihiro Furusyo; Yuichiro Eguchi; Yao-Chun Hsu; Teng-Yu Lee; Wanhua Ren; Chengyong Qin; Dae Won Jun; Hidenori Toyoda; Vincent Wai-Sun Wong; Ramsey Cheung; Qiang Zhu; Mindie H Nguyen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-03-20

7.  Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.

Authors:  Jeremy Lok Wei; Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; Grace Lai-Hung Wong; David Ka-Wai Yeung; Ruth Suk-Mei Chan; Henry Lik-Yuen Chan; Angel Mei-Ling Chim; Jean Woo; Winnie Chiu-Wing Chu; Vincent Wai-Sun Wong
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

8.  Prevalence of fatty liver disease and its risk factors in the population of South China.

Authors:  Yong-Jian Zhou; Yu-Yuan Li; Yu-Qiang Nie; Jin-Xiang Ma; Lun-Gen Lu; Sheng-Li Shi; Min-Hu Chen; Pin-Jin Hu
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

9.  Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.

Authors:  Xiaona Hu; Yiqin Huang; Zhijun Bao; Yiqian Wang; Dongmei Shi; Fang Liu; Zhanjuan Gao; Xiaofeng Yu
Journal:  BMC Gastroenterol       Date:  2012-09-14       Impact factor: 3.067

10.  Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital.

Authors:  Tao-Hsin Tung; Tsung-Hung Chang; Wei-Hsiu Chiu; Tzu-Han Lin; Hui-Chuan Shih; Ming-Huei Chang; Jorn-Hon Liu
Journal:  BMC Res Notes       Date:  2011-08-31
View more
  95 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

2.  The metabolic profiles and body composition of lean metabolic associated fatty liver disease.

Authors:  Yu-Ming Cheng; Jia-Horng Kao; Chia-Chi Wang
Journal:  Hepatol Int       Date:  2021-02-04       Impact factor: 6.047

3.  Shear wave elastography using sound touch elastography and supersonic shear imaging for liver measurements: a comparative study.

Authors:  Hongjin Xiang; Wenwu Ling; Lin Ma; Lulu Yang; Tang Lin; Yan Luo
Journal:  Quant Imaging Med Surg       Date:  2022-05

4.  Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018.

Authors:  Yunlei Deng; Qianwen Zhao; Rong Gong
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-22       Impact factor: 3.168

Review 5.  Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases.

Authors:  Winston Hernández-Ceballos; Jacqueline Cordova-Gallardo; Nahum Mendez-Sanchez
Journal:  J Clin Transl Hepatol       Date:  2021-03-08

Review 6.  Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.

Authors:  Jianan Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-05-07       Impact factor: 5.787

7.  Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES).

Authors:  A Lum Han
Journal:  Inflammopharmacology       Date:  2021-07-16       Impact factor: 4.473

8.  The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade.

Authors:  Bülent Değertekin; Nurdan Tozun; Figen Demir; Gizem Söylemez; Şirin Parkan; Ezgi Gürtay; Deniz Mutlu; Meltem Toraman; Tolga Hayrettin Seymenoğlu
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

Review 9.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

10.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.

Authors:  Shuhei Fukunaga; Dan Nakano; Takumi Kawaguchi; Mohammed Eslam; Akihiro Ouchi; Tsutomu Nagata; Hidefumi Kuroki; Hidemichi Kawata; Hirohiko Abe; Ryuichi Nouno; Koutaro Kawaguchi; Jacob George; Keiichi Mitsuyama; Takuji Torimura
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.